Related by context. All words. (Click for frequent words.) 75 Chronic Myeloid Leukemia 72 Acute Myelogenous Leukemia 71 Glioblastoma Multiforme 71 Acute Myeloid Leukemia AML 71 Chronic Lymphocytic Leukemia 71 Acute Leukemia 70 leukemia AML 70 Acute Lymphoblastic Leukemia 70 Cutaneous T 70 Chronic Myelogenous Leukemia 69 Follicular Lymphoma 69 Acute Myelogenous Leukemia AML 69 Myelodysplastic Syndrome 69 Cell Lymphoma 68 Mantle Cell Lymphoma 68 Diffuse Large B 68 Myelofibrosis 68 Myelodysplastic Syndromes 68 Chronic Lymphocytic Leukemia CLL 68 Malignant Melanoma 68 Metastatic Melanoma 67 Myelodysplastic Syndrome MDS 67 Metastatic Colorectal Cancer 67 Bevacizumab 67 B Cell Lymphoma 67 Malignant Glioma 67 Fludarabine 67 Relapsed Refractory 67 Investigational Treatment 67 Renal Cell Carcinoma 67 Diabetic Nephropathy 67 ara C 66 Advanced Melanoma 66 Acute Myeloid Leukaemia 66 acute myelogenous leukemia AML 65 Newly Diagnosed 65 Idiopathic Pulmonary Fibrosis 65 Non Hodgkin Lymphoma 65 Decitabine 65 Etanercept 65 Newly Diagnosed Multiple Myeloma 65 Lupus Nephritis 65 Hormone Refractory Prostate Cancer 65 Omacetaxine 65 HDAC Inhibitor 65 Soft Tissue Sarcoma 65 metastatic renal cell carcinoma 65 Previously Treated 65 Improves Outcomes 65 atypical hemolytic uremic syndrome 65 Non Hodgkin 65 Leukemias 65 leukemia ALL 65 lymphocytic leukemia 64 Bortezomib 64 Meets Primary Endpoint 64 acute myeloid leukemia AML 64 acute myeloid leukemia 64 Peginterferon 64 Rituximab 64 Relapsing Remitting Multiple Sclerosis 64 Glioma 64 myelodysplastic syndrome MDS 64 Rheumatoid Arthritis 64 Oral Fingolimod 64 Juvenile Rheumatoid Arthritis 64 Prolongs Survival 64 Phase IIb Trial 64 Naive Patients 64 Advanced Renal Cell 64 acute myeloid 64 Multiple Myeloma Patients 64 Relapsed Multiple Myeloma 64 Voreloxin 64 T Cell Lymphoma 64 Juvenile Idiopathic Arthritis 64 Annamycin 64 Patients Receiving 64 Cyclophosphamide 64 Enzastaurin 64 Squamous Cell Carcinoma 64 SPRYCEL ® 64 Cloretazine 64 Idiopathic Thrombocytopenic Purpura ITP 64 cell lymphoma CTCL 64 Antitumor Activity 64 Phase 2b Clinical Trial 64 Investigational Drug 64 Relapsing Multiple Sclerosis 64 Adjuvant Treatment 64 metastatic malignant 64 Philadelphia Chromosome Positive 64 Metastatic Prostate Cancer 64 PKC# 63 Disease Progression 63 Anthracycline 63 Neovascular Age Related Macular 63 Sapacitabine 63 Combination Treatment 63 Phase 2b Study 63 thalidomide Thalomid 63 Carcinoma 63 Previously Untreated 63 Melphalan 63 galiximab 63 Monotherapy 63 Phase III Trials 63 mRCC 63 Epratuzumab 63 Pulmonary Arterial Hypertension 63 Major Depressive Disorder 63 Mouse Model 63 Randomized Phase 63 Acute Lymphocytic Leukemia 63 Myeloma Patients 63 Sipuleucel T 63 Ulcerative Colitis 63 B Cell Malignancies 63 Romidepsin 63 Rheumatoid Arthritis Patients 63 Novel Oral 63 leukemia CLL 63 Tyrosine Kinase Inhibitor 63 Acute Myeloid Leukaemia AML 63 Epidermal Growth Factor Receptor 63 Osteosarcoma 63 Pivotal Phase III 63 Bosutinib 63 Lung Cancer Patients 63 Amrubicin 63 Pralatrexate 63 Aurora Kinase 63 Progressive Multifocal Leukoencephalopathy 63 cutaneous T 63 Predict Response 63 Acute Lymphoblastic Leukaemia 63 Pivotal Phase 63 Vidaza azacitidine 63 Improve Survival 63 Hodgkin lymphoma NHL 63 Unresectable 63 Antiangiogenic 63 Tumor Necrosis Factor 63 Nilotinib 63 Autologous Stem Cell Transplantation 63 Pegylated Interferon 63 Severe Sepsis 62 Metastatic Renal Cell Carcinoma 62 Alemtuzumab 62 gastrointestinal stromal tumor GIST 62 Gaucher Disease 62 Improves Survival 62 Placebo Controlled Study 62 Dasatinib 62 malignant ascites 62 Tyrosine Kinase Inhibitors 62 Refractory Hodgkin Lymphoma 62 Pharmacokinetics PK 62 RNAi Therapeutic 62 atypical Hemolytic Uremic Syndrome 62 receptor tyrosine kinase inhibitor 62 Adjuvant Chemotherapy 62 Castration Resistant Prostate Cancer 62 follicular lymphoma FL 62 Eculizumab 62 relapsed leukemia 62 dasatinib Sprycel ® 62 refractory acute myeloid 62 Immunosuppression 62 Velcade bortezomib 62 Epstein Barr Virus 62 Chronic lymphocytic leukemia 62 Plus Ribavirin 62 adalimumab Humira 62 Fabry Disease 62 Complicated Skin 62 recurrent glioblastoma multiforme 62 antibody MAb 62 Friedreich Ataxia 62 Chemotherapy Improves 62 Brentuximab Vedotin SGN 62 Hepatocellular Carcinoma 62 familial amyloidotic polyneuropathy FAP 62 Patients Treated With 62 Atypical Hemolytic Uremic Syndrome 62 Azacitidine 62 Radioimmunotherapy 62 Stomach Cancer 62 Adalimumab 62 alfa 2a 62 Enzyme Replacement Therapy 62 chronic eosinophilic leukemia 62 chronic myeloid 62 lymphoma CTCL 62 Breast Cancer Recurrence 62 Survival Benefit 62 Aflibercept 62 Severe Asthma 62 HER2 Positive Breast Cancer 62 azacytidine 62 gastrointestinal stromal tumors GIST 62 Hepatocellular Carcinoma HCC 62 metastatic malignant melanoma 62 hypereosinophilic syndrome 62 Kinase Inhibitor 62 systemic juvenile idiopathic 62 unresectable stage 62 Diabetic Patients 62 Endometrial Cancer 62 Clinical Trial Results 62 Ozarelix 62 Zarnestra 62 CYT# potent vascular disrupting 62 Cloretazine R VNP#M 62 Treatment Regimen 62 chronic lymphocytic leukemia CLL 62 Colorectal Cancer Patients 62 Temsirolimus 62 Relapsed Refractory Aggressive 62 Boceprevir 62 Advanced Colorectal Cancer 62 demethylating agent 62 refractory chronic lymphocytic 61 Pooled Analysis 61 indolent follicular non 61 T#I [002] 61 Hodgkin Lymphoma 61 Chronic Myeloid Leukemia CML 61 myelodysplastic syndromes MDS 61 complement inhibitor eculizumab 61 Drug Candidate 61 Dose Escalation 61 Tasigna nilotinib 61 idiopathic thrombocytopenic purpura 61 Acute myeloid leukemia 61 prostate cancer HRPC 61 mycosis fungoides 61 Ovarian Cancer Patients 61 cisplatin chemotherapy 61 Pivotal Study 61 relapsed multiple myeloma 61 eosinophilic asthma 61 Multiple Myeloma 61 Monoclonal Antibody 61 Fluorouracil 61 hormone LHRH antagonist 61 Metastatic Pancreatic Cancer 61 ISTODAX ® 61 Pivotal Trials 61 Autoimmune Disease 61 Treatment Naive 61 Phase III Clinical Trial 61 lymphoblastic leukemia 61 Treatment Naive Patients 61 gastrointestinal stromal tumor 61 Crohn Disease 61 Relapsed Refractory Multiple Myeloma 61 Emerging Therapies 61 myeloproliferative neoplasms 61 Gene Mutation 61 Herceptin trastuzumab 61 Advanced Prostate Cancer 61 Cytarabine 61 Elderly Patients 61 systemic mastocytosis 61 5 Fluorouracil 61 Clofarabine 61 metastatic GIST 61 Slow Progression 61 Pemetrexed 61 Chronic Sinusitis 61 Treated Patients 61 Bladder Cancer 61 relapsed MM 61 Degarelix 61 Study Evaluating 61 Anti Tumor 61 Prospective Randomized 61 Enlarged Prostate 61 Phase IIa Clinical Trial 61 Chronic Hepatitis C 61 Mitoxantrone 61 Spinal Muscular Atrophy SMA 61 Well Tolerated 61 diffuse intrinsic pontine glioma 61 Golimumab 61 recurrent glioma 61 lupus nephritis 61 Renal Impairment 61 Hepatitis C Virus 61 Chronic Heart Failure 61 myelofibrosis polycythemia vera 61 non metastatic osteosarcoma 61 Demonstrates Potent 61 Therapy Evaluation 61 Improved Survival 61 HER2 positive metastatic breast 61 Dose Escalation Study 61 gefitinib Iressa 61 Bendamustine 61 Gleevec resistant 61 Inflammatory Markers 61 Natalizumab 61 relapsing multiple sclerosis 61 PTLD 61 Solid Tumors 61 Novel Mechanism 61 Lenalidomide 61 Acute Promyelocytic Leukemia 61 myelodysplastic syndrome 61 Trastuzumab 61 Erlotinib 60 Capecitabine 60 Pancreatic Cancer 60 metastatic gastric 60 cetuximab Erbitux R 60 Cimzia ® certolizumab pegol 60 Toxicities 60 Insulin Resistance 60 Onrigin 60 idiopathic thrombocytopenic purpura ITP 60 gastrointestinal stromal tumors 60 BARACLUDE ® 60 Combo Therapy 60 Lennox Gastaut syndrome 60 Neoadjuvant 60 Potent Anti 60 Phase IIb Clinical Trial 60 Leber Congenital Amaurosis LCA 60 Leber Hereditary Optic Neuropathy 60 erlotinib Tarceva ® 60 Gemcitabine 60 Irinotecan 60 Inhaled Corticosteroids 60 Interferon beta 1a 60 Treating Chronic 60 relapsed AML 60 Phase 2a Trial 60 Generalized Anxiety Disorder 60 Prostate Cancer Patients 60 hepatoblastoma 60 Investigational Agent 60 cancer mCRC 60 Safinamide 60 Waldenstrom macroglobulinemia 60 Community Acquired Pneumonia 60 Breast Cancer Treatment 60 prostate cancer CRPC 60 Hepatotoxicity 60 calcineurin inhibitor 60 Pegylated Liposomal Doxorubicin 60 Dacogen injection 60 Cloretazine ® 60 non hodgkin lymphoma 60 Hepatic Encephalopathy 60 Overactive Bladder 60 Rheumatoid Arthritis RA 60 Single Dose 60 Gemzar ® 60 Cloretazine R 60 Initiate Phase 60 Resistant Hypertension 60 alefacept 60 Vicriviroc 60 Pertuzumab 60 Acute Ischemic Stroke 60 relapsed acute lymphoblastic 60 metastatic kidney 60 Non Hodgkins Lymphoma 60 investigational monoclonal antibody 60 Phase III Trial 60 smoldering myeloma 60 Elotuzumab 60 Retreatment 60 Randomized Phase II 60 Kidney Transplant Recipients 60 NDA Submission 60 cisplatin gemcitabine 60 Systemic Sclerosis 60 decitabine 60 Anaplastic 60 Torisel 60 Orally Active 60 vWD 60 Lung Cancer Drug 60 severe oral mucositis 60 Platinol ® 60 cilengitide 60 PNP inhibitor 60 Doxil ® 60 bevacizumab Avastin ® 60 juvenile myelomonocytic leukemia 60 Burkitt Lymphoma 60 chronic idiopathic 60 relapsed refractory multiple myeloma 60 aflibercept VEGF Trap 60 Epoetin Alfa 60 myeloid metaplasia 60 Secondary Hyperparathyroidism 60 Allergic Rhinitis 60 Pediatric Patients 60 Antiviral Activity 60 glioblastoma multiforme GBM 60 JAK Inhibitor 60 Dacogen decitabine 60 INCB# [001] 60 Rituxan rituximab 60 Hormone Receptor Positive 60 Adjuvant Therapy 60 Investigational Compound 60 Drug Shows Promise 60 Diabetic Neuropathic Pain 60 melphalan prednisone 60 acute promyelocytic leukemia 60 Eltrombopag 60 Fulvestrant 60 Cytotoxic 59 II Clinical Trial 59 Renal Anemia 59 Radiofrequency Ablation RFA 59 Androgen Deprivation Therapy 59 denileukin diftitox 59 Pharmacokinetic Study 59 Sprycel dasatinib 59 Hepatitis C Infection 59 Partial Onset Seizures 59 Xelox 59 Respiratory Syncytial Virus 59 BRIM2 59 Chronic HCV 59 Skeletal Muscle 59 Vandetanib 59 IL# PE#QQR 59 MGd 59 Duchenne muscular dystrophy DMD 59 HCV Genotype 59 achieved CCyR 59 Vidaza ® 59 Myelodysplasia 59 QLT# 59 Romiplostim 59 Paroxysmal Nocturnal Hemoglobinuria PNH 59 systemic anaplastic large 59 Parkinson Disease PD 59 acute leukemia AML 59 Randomized Double blind 59 AVONEX ® 59 myelodysplastic myeloproliferative diseases 59 basiliximab 59 Hepatitis B Virus 59 Treatment Naïve 59 Protease Inhibitor 59 Gleevec imatinib mesylate 59 Astrocytoma 59 Mipomersen 59 CIMZIA TM 59 SJIA 59 Carboplatin Paclitaxel 59 HuMax EGFr 59 ORENCIA ® 59 Subgroup Analysis 59 Aliskiren 59 biliary tract cancer 59 Lung Cancers 59 pheochromocytoma 59 SNT-MC#/idebenone 59 refractory indolent non 59 ZACTIMA 59 Major Depressive Disorder MDD 59 Troxatyl 59 Rilonacept 59 Folfox 59 Combination Therapy 59 Phase 2b Trial 59 Paraplatin ® 59 imatinib Gleevec ® 59 Graft Versus Host 59 Tanespimycin 59 Shows Promising 59 hematological malignancy 59 KRN# 59 Treatment Resistant 59 Lymphocytic 59 Proves Effective 59 invasive candidiasis 59 multiple myeloma MM 59 malignant pleural mesothelioma 59 efalizumab 59 Cardiovascular Outcomes 59 post herpetic neuralgia PHN 59 Initiate Clinical Trial 59 Patients Treated 59 deletion 5q 59 bladder carcinoma 59 Cognitive Impairment 59 lymphoid malignancies 59 HRPC 59 JMML 59 metastatic hormone refractory 59 Hsp# Inhibitor 59 acute promyelocytic leukemia APL 59 Neoadjuvant Chemotherapy 59 Hedgehog Pathway Inhibitor 59 Duchenne Muscular Dystrophy DMD 59 Serious Infections 59 Tocilizumab 59 MEK inhibitor 59 Chronic Myelogenous Leukemia CML 59 recurrent NSCLC 59 Receives Orphan Drug Designation 59 Heterozygous Familial Hypercholesterolemia 59 Gastrointestinal Stromal Tumors 59 Janus kinase 59 tyrosine kinase inhibitor 59 Aryplase 59 TORISEL 59 Carcinoid Syndrome 59 Ofatumumab 59 FDA Okays 59 Proxinium TM 59 Roche Actemra 59 Intravitreal 59 Xanafide 59 cutaneous T cell 59 Phase 2a Clinical Trial 59 Chronic Insomnia 59 Hemophilia B 59 myeloid leukemia 59 Progenitor Cells 59 Bipolar Depression 59 rALLy 59 essential thrombocythemia 59 Dapagliflozin 59 Multicenter Randomized 59 Metastases 59 Combination REOLYSIN R 59 relapsing remitting MS RRMS 59 Signaling Pathway 59 Hodgkin lymphoma HL 59 Plaque Psoriasis 59 Severe Primary IGFD 59 Targeted Therapy 59 haematologic 59 Kinase Inhibitors 59 HERCEPTIN 59 cutaneous squamous cell carcinoma 59 azacitidine 59 Phase III Pivotal 59 VNP#M 59 Lung Cancer Trial 59 FOLOTYN ® 59 EGFR TKI 59 Preclinical Data 59 heavily pretreated 59 LHON 59 refractory myeloma 59 Randomized Double Blind 59 CHOP chemotherapy 59 rituximab Rituxan 59 acute myelogenous 59 purpura ITP 59 Basal Cell Carcinoma 59 CLL SLL 59 Sustained Efficacy 59 Kinoid 59 mTOR inhibitor 59 follicular Non Hodgkin 59 Long Term Efficacy 59 Acute myeloid leukemia AML 59 Predict Risk 59 Cytotoxicity 59 generation purine nucleoside 59 HoFH 59 hypophosphatasia 59 multiple myeloma 59 DIPG 59 Kidney Transplant Patients 59 Anti Tumor Activity 59 Maribavir 58 TNF Blockers 58 GW# [003] 58 lumiliximab 58 intratumoral injection 58 Growth Hormone Deficiency 58 autoimmune hemolytic anemia 58 chronic granulomatous disease 58 Introgen ADVEXIN 58 Clostridium difficile Infection 58 Pervasive Developmental Disorder 58 Cyclooxygenase 2 58 Reovirus 58 secondary hyperparathyroidism 58 Psoriatic Arthritis 58 Lennox Gastaut Syndrome 58 paclitaxel Taxol R 58 HBeAg negative 58 lenalidomide Revlimid R 58 Lubiprostone 58 retinal vein occlusion 58 Trial Evaluating 58 Knee Osteoarthritis 58 chronic myeloid leukemia CML 58 induced anemia 58 Relapsed 58 biologic therapy 58 metastatic colorectal 58 Ranolazine 58 Imatinib 58 tuberous sclerosis complex 58 Irritable Bowel Syndrome IBS 58 acute lymphatic leukemia 58 nonsmall cell lung cancer 58 chronic myelogenous leukemia CML 58 Peginterferon alfa 2b 58 infliximab Remicade 58 immune thrombocytopenic purpura 58 cis retinoic acid 58 chronic immune thrombocytopenic 58 Genentech Rituxan 58 pertuzumab 58 mCRC patients 58 Systemic Lupus Erythematosus 58 anaplastic astrocytoma 58 Nodular 58 Slows Progression 58 Morquio 58 hepatocellular cancer 58 Hypercholesterolemia 58 Anticancer Activity 58 juvenile idiopathic arthritis 58 hemophagocytic lymphohistiocytosis 58 fallopian tube carcinoma 58 Glioblastoma Multiforme GBM 58 Peripheral Artery Disease 58 Esophageal Cancer 58 autoantibody positive 58 Septic Shock 58 Double Blind Placebo 58 pulmonary hypertension PH 58 Monoclonal Antibodies 58 Glioblastoma 58 Controlled Study 58 acute leukemias 58 Present Preclinical Data 58 Advanced Pancreatic Cancer 58 neuroendocrine cancers 58 Newly Diagnosed Patients 58 Cytomegalovirus 58 nab paclitaxel 58 remission induction 58 Anti TNF 58 Malignancies 58 Treatment Shows Promise 58 Successfully Completes Phase 58 PEGylated Fab fragment 58 Metastatic breast cancer 58 Gastric Cancer 58 Pulmonary Hypertension 58 STELARA TM 58 metastatic renal 58 lymphoma leukemia 58 acute GvHD 58 Renal Function 58 Abatacept 58 pediatric acute lymphoblastic 58 myelodysplastic syndromes 58 Heart Failure Patients 58 Multiple Myeloma MM 58 Drug Combo 58 icatibant 58 sorafenib Nexavar ® 58 Taxane 58 Nexavar sorafenib 58 systemic lupus erythematosus SLE 58 DOXIL 58 DEB# 58 Lacosamide 58 Alocrest 58 TELINTRA 58 Genetic Disorder 58 homozygous familial hypercholesterolemia 58 dasatinib Sprycel 58 Phase III Clinical Trials 58 Trabectedin 58 5 fluorouracil leucovorin 58 Initiates Clinical Trial 58 ST Elevation Myocardial 58 Li Fraumeni Syndrome 58 abacavir Ziagen 58 trans retinoic acid 58 pan HDAC inhibitor 58 posterior uveitis 58 refractory NSCLC 58 Zolinza 58 refractory cutaneous T 58 elacytarabine 58 Breast Cancers 58 Postmenopausal Osteoporosis 58 ACE Inhibitors 58 Glufosfamide 58 Acute Renal Failure 58 demonstrated antitumor activity 58 Alzheimer Disease AD 58 MELAS 58 Hodgkin Disease 58 sunitinib Sutent ® 58 Critical Limb Ischemia 58 Respiratory Virus 58 Herpes Simplex Virus 58 Crohn disease CD 58 recurrent glioblastoma 58 Cell Lymphoma CTCL 58 hypomethylating agents 58 Ischemic Stroke 58 immune thrombocytopenic purpura ITP 58 Tumor Suppressor 58 Preclinical Models 58 Fungal Infections 58 Allogeneic 58 Gene Therapy Trial 58 Peginterferon Alfa 2b 58 Adjunctive Therapy 58 ON #.Na 58 Fludara 58 See CLINICAL PHARMACOLOGY 58 Bipolar Mania 58 invasive aspergillosis 58 Myelodysplastic Syndromes MDS 58 PEG IFN 58 juvenile myoclonic epilepsy 58 HER2 Positive 58 Temodar ® 58 anthracyclines taxanes 58 Cell Lung Cancer 58 Traficet EN 58 Angioedema 58 PROCRIT R 58 overactive bladder syndrome 58 Interferon Beta 58 Anticancer Drugs 58 Aviptadil 58 Noxafil 58 erythropoietic 58 Alzheimers Disease 58 Oral Formulation 58 Hepatitis C Patients 58 tumors GIST 58 AA Amyloidosis 58 pemphigus vulgaris 58 Gene Linked 58 Evoltra ® 58 Myeloid 58 advanced nonsquamous NSCLC 58 Shows Promise Against 58 metastatic ovarian cancer 58 PROCRIT ® 58 monoclonal antibody conjugated 58 Randomized Study 58 Cetuximab 58 Tumor Response 58 Laquinimod 58 AEG# 58 multiforme 58 tyrosine kinase inhibitors TKIs 58 castrate resistant prostate cancer 58 Diabetic Neuropathy 58 Placebo Controlled Trial 58 alpha 2a 58 Plecanatide 58 Metastatic Breast Cancer 58 gastrointestinal stromal tumors GISTs 58 lymphoblastic lymphoma 58 Cholangiocarcinoma 58 mapatumumab 58 Paclitaxel Carboplatin 58 HCV Protease Inhibitor 58 Asthma COPD 58 Fludara ® 58 COPAXONE ® 58 peritumoral brain edema 58 malignant pleural mesothelioma MPM 58 Schizophrenia Drug 58 JAK2 Inhibitor 58 Vasculitis 58 Dupuytren Contracture 58 Unfractionated Heparin 58 Inflammatory Diseases 58 Dendritic Cells 58 vincristine doxorubicin 58 Rheumatoid Arthritis Drug 58 squamous cell carcinoma SCC 58 PEGINTRON TM 58 dasatinib 58 ribavirin RBV 58 thrombocythemia 58 LHRH receptor positive 58 Celgene Revlimid 58 Ischemic 58 Pancreatic Adenocarcinoma 58 Is Well Tolerated 58 MYCAMINE 58 chemotherapy cisplatin 58 Tarceva erlotinib 58 Synovial Sarcoma 58 TACI Ig 58 Liver Metastases 57 relapsed ALL 57 baminercept 57 Study Shows Promise 57 measurable tumor regressions 57 ELOXATIN 57 Pathway Inhibitor 57 BR.# 57 Tolerability 57 Hemorrhagic Stroke 57 Talabostat 57 tigecycline 57 Sjogren Syndrome 57 Autoimmune Diseases 57 Chemotherapy Regimen 57 Kit CD# positive 57 omacetaxine mepesuccinate 57 Neulasta ® 57 essential thrombocythemia ET 57 Receptor Antagonists 57 myelogenous leukemia 57 Thyroid Cancer 57 Dose Ranging Study 57 Appears Safe 57 Immunomodulatory 57 Cystinosis 57 myeloproliferative diseases 57 castration resistant prostate cancer 57 thymoma 57 Invasive Breast Cancer 57 Sorafenib 57 evaluating mipomersen 57 Neuroendocrine Tumors 57 Denufosol 57 fibromyalgia syndrome 57 Crohn disease 57 Aplidin 57 Adenocarcinoma 57 Medulloblastoma 57 metastatic castration resistant 57 Dyskinesia 57 chronic rheumatic 57 proteasome inhibitor bortezomib 57 IMA# 57 Bayer Nexavar 57 Atopic Dermatitis 57 TEMODAL 57 Copegus ribavirin 57 FOLFIRI 57 imatinib Gleevec 57 oxypurinol 57 Polymerase Inhibitor 57 Chemoradiation 57 pancreatic adenocarcinoma 57 Neuroprotection 57 follicular lymphomas 57 YONDELIS 57 systemic lupus erythematosus 57 Valopicitabine 57 pentostatin 57 Systemic Delivery 57 Azedra 57 Infected Patients 57 Acute Pancreatitis 57 lung fibrosis 57 Interferon Alfa 57 Controlled Trial 57 MabThera Rituxan 57 Subtypes 57 Chronic Hepatitis B 57 ThermoDox R 57 Vaccine Candidate 57 Duchenne Becker 57 Perifosine 57 haematologic malignancies 57 Prostate Cancer Vaccine 57 INCB# [003] 57 Node Positive 57 Diabetic Macular Edema 57 enzastaurin 57 docetaxel cisplatin 57 acute lymphoblastic 57 Factor Receptor 57 RNAi Therapeutics 57 pegylated interferon alpha 57 ZOLINZA 57 hormone refractory metastatic prostate 57 docetaxel Taxotere 57 Granted Orphan Drug 57 Apaziquone 57 5 FU leucovorin 57 cell carcinoma RCC 57 FOLFOX6 57 acute lymphoblastic leukemia 57 fosbretabulin 57 ganetespib 57 Archexin 57 SHPT 57 Autoimmune Disorders 57 Sanfilippo Syndrome 57 relapsed ovarian cancer 57 stage IIIB 57 Lamotrigine 57 E1 INT TM 57 insulin glulisine 57 Advanced Ovarian Cancer 57 unstable angina UA 57 Corticosteroid 57 Chronic Fatigue Syndrome CFS 57 Antitumor activity 57 cetuximab Erbitux ® 57 Tezampanel 57 Statistically Significant 57 refractory metastatic colorectal cancer 57 Estrogen Receptor 57 Breast Cancer Patients 57 Bezielle 57 Postherpetic Neuralgia 57 metastatic renal cell 57 Topotecan 57 Initiates Clinical 57 trastuzumab Herceptin ® 57 Mutation Analysis 57 Pamidronate 57 Initiates Phase II 57 Dyslipidemia 57 Oritavancin 57 ulcerative colitis UC 57 metastatic colorectal carcinoma 57 Adjunctive 57 CTAP# Capsules 57 Primary Immune Deficiency 57 terlipressin 57 paclitaxel Taxol 57 Bosentan 57 keloid scarring 57 refractory gout 57 standard chemotherapy regimen 57 refractory prostate cancer 57 Stem Cell Treatment 57 Advanced Solid Tumors 57 bortezomib Velcade R 57 Ph + acute lymphoblastic 57 Dilated Cardiomyopathy 57 Study Showed 57 Presents Preclinical Data 57 metastatic castrate resistant 57 Myelodysplastic syndrome 57 IV Busulfex 57 selective modulator 57 relapsed refractory 57 FOLFOX chemotherapy 57 alpha interferons 57 Anticancer Drug 57 estramustine 57 Ribavirin causes 57 luteinizing hormone releasing 57 papillary renal cell carcinoma 57 relapsed CLL 57 Ischaemic 57 Lymphoid 57 Systemic Lupus Erythematosus SLE 57 Gene Variant 57 familial hypercholesterolemia 57 Spinal Muscular Atrophy 57 RhuDex 57 pomalidomide 57 Migraine Pain 57 exocrine pancreatic insufficiency EPI 57 Autoimmune 57 myeloproliferative disorder 57 Wilms Tumor 57 Navelbine ® 57 NMIBC 57 XYOTAX TM 57 Therapeutic Vaccine 57 mycophenolate mofetil 57 pancreatic insufficiency 57 glioblastoma brain tumor 57 untreated de novo 57 Systemic Juvenile Idiopathic 57 Tipranavir 57 Metastatic 57 interferon therapy 57 p# biomarker 57 Initiates Phase 2b 57 unresectable inoperable 57 opioid induced constipation OIC 57 Acute Radiation Syndrome 57 Ankylosing Spondylitis 57 leukoencephalopathy 57 immunomodulator 57 Initiate Phase III 57 HER2 positive breast cancer